Earnings Feed
Start Free
Beta Bionics, Inc.·4

Jun 5, 6:05 PM ET

Hopman Mark 4

Research Summary

AI-generated summary

Updated

Beta Bionics (BBNX) CCO Mark Hopman Sells 275 Shares

What Happened
Mark Hopman, Chief Commercial Officer of Beta Bionics (BBNX), sold 275 shares on 2026-06-04 at $12.31 per share, generating proceeds of approximately $3,385. The transaction is a sale (code S) and was reported on a Form 4 filed 2026-06-05.

Key Details

  • Transaction date and price: 2026-06-04, 275 shares sold at $12.31 each.
  • Total proceeds: ~$3,385.
  • Sale executed pursuant to a Rule 10b5-1 plan adopted May 13, 2025 (footnote F1).
  • Shares owned after the transaction: not specified in the provided filing excerpt.
  • Filing timeliness: Form 4 was filed the next day (2026-06-05), consistent with SEC timeliness requirements.

Context
A sale under a Rule 10b5-1 plan is a pre-arranged trade and is often treated as routine rather than a direct signal of the insider's near-term view. Sales are generally less informative than purchases for gauging insider conviction.